Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device’s patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC
Europace · 01.11.2024 · 26 (11)
DOI: 10.1093/europace/euae272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, online erschienen am 31.10.2024. Verfasst von Petr Peichl und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, IKEM, Vídeňská 1958/9, Prague, Czech Republic. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Catheter Ablation, Heart Failure. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure. Although these devices effectively improve survival, atrial and ventricular arrhythmias are common with a prevalence of 20–50% at one year after LVAD implantation. Arrhythmias predispose these patients to additional risk and are associated with considerable morbidity from recurrent implantable cardioverter-defibrillator shocks, progressive failure of the unsupported right ventricle, and herald an increased risk of mortality. Management of patients with arrhythmias and LVAD differs in many aspects from the general population heart failure patients. These include ruling out the reversible causes of arrhythmias that in LVAD patients may include mechanical irritation from the inflow cannula and suction events. For patients with symptomatic arrhythmias refractory to medical treatment, catheter ablation might be relevant. There are specific technical and procedural challenges perceived to be unique to LVAD-related ventricular tachycardia (VT) ablation such as vascular and LV access, signal filtering, catheter manoeuvrability within decompressed chambers, and electroanatomic mapping system interference. In some patients, the arrhythmogenic substrate might not be readily accessible by catheter ablation after LVAD implantation. In this regard, the peri-implantation period offers a unique opportunity to surgically address arrhythmogenic substrate and suppress future VT recurrences. This document aims to address specific aspects of the management of arrhythmias in LVAD patients focusing on anti-arrhythmic drug therapy and ablations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, IKEM, Vídeňská 1958/9, Prague, Czech Republic.
- Heart Institute at Hospital Universitari Germans Trias i Pujol, CIBERCV, Badalona, Spain.
- Clinic for Arrhythmology, Klinikum Nuernberg Süd, University Hospital of the Paracelsus Medical University, Nuernberg, Germany.
- Institute of Emergency for Cardiovascular Diseases, 'C.C.Iliescu' Bucharest, Romania.
- University of Medicine Carol Davila, Bucharest, Romania.
- Leiden University Medical Center, Leiden, The Netherlands.
ORCID-Profile: Petr Peichl, Antoni Bayes-Genis, Thomas Deneke, Ovidiu Chioncel, Marta deRiva, Maria Generosa Crespo-Leiro, Antonio Frontera, Finn Gustafsson, Raphaël P Martins, Matteo Pagnesi, Philippe Maury, Mark C Petrie, Frederic Sacher, Offer Amir
Zitieren
APA
Peichl, P., Bayes-Genis, A., Deneke, T., Chioncel, O., deRiva, M., Crespo-Leiro, M. G., Frontera, A., Gustafsson, F., Martins, R. P., Pagnesi, M., Maury, P., Petrie, M. C., Sacher, F., Amir, O., Di Biase, L., Deisenhofer, I., Gasparetti, A., Hocini, M., Costa, F. M., …, & Wakili, R. (2024). Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device’s patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC. Europace, 26(11). https://doi.org/10.1093/europace/euae272
Vancouver
Peichl P, Bayes-Genis A, Deneke T, Chioncel O, deRiva M, Crespo-Leiro MG, et al. Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device’s patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC. Europace. 2024;26(11). doi:10.1093/europace/euae272
BibTeX
@article{Peichl2024,
author = {Peichl, Petr and Bayes-Genis, Antoni and Deneke, Thomas and Chioncel, Ovidiu and deRiva, Marta and Crespo-Leiro, Maria Generosa and Frontera, Antonio and Gustafsson, Finn and Martins, Raphaël P and Pagnesi, Matteo and Maury, Philippe and Petrie, Mark C and Sacher, Frederic and Amir, Offer and Di Biase, Luigi and Deisenhofer, Isabel and Gasparetti, Alessio and Hocini, Mélèze and Costa, Francisco Moscoso and Moura, Brenda and Skouri, Hadi and Tocchetti, Carlo Gabriele and Volterrani, Maurizio and Wakili, Reza},
title = {Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device’s patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC},
journal = {Europace},
year = {2024},
volume = {26},
number = {11},
doi = {10.1093/europace/euae272}
}
EUVIMED